Neurocognitive Impairment in HIV-Infected Naïve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation

Table 2

CSF inflammation markers dynamics.

CSF concentration (pg/mL)	HAND group	Controls	𝑃
IL-6 BL	3.50 (2.96–6.22)	0.31 (0.18–1.04)	0.06
IL-6 W12	6.00 (2.25–5.75)	1.00 (0.00–1.52)	0.06
TGF-β1 BL	0.11 (0.00–11.75)	12.40 (0.00–24.10)	ns
TGF-β1 W12	0.10 (0.00–5.20)	13.50 (9.25–16.75)	ns
TGF-β2 BL	59.00 (0.00–87.20)	99.12 (20.10–147.00)	ns
TGF-β2 W12	46.11 (41.72–61.11)	79.06 (69.13–92.23)	ns
MIP-1α BL	0.70 (0.00–2.86)	0.10 (0.00–0.12)	0.05
MIP-1α W12	1.00 (1.00–6.50)	0.10 (0.00–0.22)	0.05
MIP-1β BL	2.74 (2.14–7.30)	1.44 (0.94–2.13)	0.03
MIP-1β W12	2.65 (1.42–1.87)	1.61 (0.48–1.87)	0.05
MCP-1 log10 BL	2.85 (2.84–3.06)	2.69 (2.65–2.75)	0.06
MCP-1 log10 W12	2.63 (2.61–2.79)	2.64 (2.61–2.68)	ns